The new generation of Hong Kong police officers will need “iron bones” in the face of unrelenting “oppression by hostile foreign forces”, the security minister has said. Secretary for Security Chris Tang Ping-keung, speaking at the force’s passing-out parade on Saturday, was also moved to tears when he recalled the force’s efforts to recover the human remains of those killed in the Wang Fuk Court ...
The new generation of Hong Kong police officers will need “iron bones” in the face of unrelenting “oppression by hostile foreign forces”, the security minister has said. Secretary for Security Chris Tang Ping-keung, speaking at the force’s passing-out parade on Saturday, was also moved to tears when he recalled the force’s efforts to recover the human remains of those killed in the Wang Fuk Court blaze last November. “The oppression by hostile foreign forces will not stop. Those who are anti-China and want to destabilise Hong Kong will also not stop,” he said. Advertisement “When you are facing threats, are you willing to stand firm and speak the truth?” He added that in light of these struggles, officers would need an indestructible set of “iron bones”. Advertisement The security minister also cited remarks by Chinese President Xi Jinping, who said that it was the force’s “sacred duties” to safeguard national security and social stability, as well as to protect the happiness and peace of the people.
Townsquare Capital LLC lessened its position in shares of Tesla, Inc. (NASDAQ:TSLA - Free Report) by 58.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,577 shares of the electric vehicle producer's stock after selling 12,021 shares during the period. Townsquare Capital LLC's holdings in Tesla were worth $3,814,000 as of...
Townsquare Capital LLC lessened its position in shares of Tesla, Inc. (NASDAQ:TSLA - Free Report) by 58.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,577 shares of the electric vehicle producer's stock after selling 12,021 shares during the period. Townsquare Capital LLC's holdings in Tesla were worth $3,814,000 as of its most recent filing with the Securities and Exchange Commission. Several other large investors have also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in Tesla by 11.8% in the 4th quarter. Brighton Jones LLC now owns 87,929 shares of the electric vehicle producer's stock worth $35,509,000 after acquiring an additional 9,293 shares during the last quarter. Revolve Wealth Partners LLC increased its position in shares of Tesla by 21.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 5,317 shares of the electric vehicle producer's stock worth $2,147,000 after purchasing an additional 931 shares during the last quarter. Bison Wealth LLC raised its stake in Tesla by 52.2% in the fourth quarter. Bison Wealth LLC now owns 10,368 shares of the electric vehicle producer's stock valued at $4,187,000 after purchasing an additional 3,558 shares in the last quarter. Sivia Capital Partners LLC lifted its position in Tesla by 9.1% during the second quarter. Sivia Capital Partners LLC now owns 12,135 shares of the electric vehicle producer's stock valued at $3,855,000 after purchasing an additional 1,011 shares during the last quarter. Finally, AGP Franklin LLC grew its stake in Tesla by 21.2% in the 2nd quarter. AGP Franklin LLC now owns 4,861 shares of the electric vehicle producer's stock worth $1,544,000 after buying an additional 851 shares in the last quarter. 66.20% of the stock is owned by institutional investors. Get Tesla alerts: Sign Up Tesla Price Performance TSLA opened at $430.41 on Friday. The company has a debt-to-equi...
Novak Djokovic had barely even begun to digest the madness of one of his great late-career victories, still fighting back tears on Rod Laver Arena, when he was asked by his on-court interviewer to cast his mind ahead to the final. After his monumental five-set Australian Open semi-final win over Jannik Sinner, where he matched the quality, intensity and athleticism of one of the two commanding pla...
Novak Djokovic had barely even begun to digest the madness of one of his great late-career victories, still fighting back tears on Rod Laver Arena, when he was asked by his on-court interviewer to cast his mind ahead to the final. After his monumental five-set Australian Open semi-final win over Jannik Sinner, where he matched the quality, intensity and athleticism of one of the two commanding players in men’s tennis, he was immediately reminded that Carlos Alcaraz, the other dominant player, was next: “I just hope that I’ll have enough gas to stay toe to toe with him,” said Djokovic. “That’s my desire, then let the gods decide the winner.” He was deadly serious. Even now, with so much mileage in his legs at 38 years old, Djokovic has never doubted his ability to still match the level of the best player in the world. His durability, however, is another issue altogether and he struggled to recover physically from tough best of five sets matches throughout last season. It cost Djokovic so much energy to put Sinner away after four hours in such a high-intensity match. Even before he thinks about his prodigious opponent across the net, Djokovic’s biggest concern is his recovery. View image in fullscreen Carlos Alcaraz revels in the adulation after winning his semi-final against Alexander Zverev. Photograph: Hollie Adams/Reuters Fortunately for the oldest Australian Open men’s finalist in history, Alcaraz at least shares similar worries. Around an hour before Djokovic and Sinner entered the court on Friday, Alcaraz added yet another match to his portfolio of improbable comeback victories, fighting back from cramps and a fifth-set deficit break to reach his first slam final in Melbourne. Considering how much of his movement he recovered by the end, it seems likely that Alcaraz’s physical issues against Zverev were merely cramps. With rest and diligent recovery, many players often do not have any lingering physical issues after cramping episodes, particularly 22-year-old p...
To activate the text-to-speech service, please first agree to the privacy policy below. Taipei, Jan. 31 (CNA) CTBC Financial Holding Co. paid the highest compensation to its board members among companies listed on the Taiwan Stock Exchange (TWSE) in 2024, with contract chipmaker Taiwan Semiconductor Manufacturing Co. (TSMC) ranking third, according to TWSE data. The data released Friday showed tha...
To activate the text-to-speech service, please first agree to the privacy policy below. Taipei, Jan. 31 (CNA) CTBC Financial Holding Co. paid the highest compensation to its board members among companies listed on the Taiwan Stock Exchange (TWSE) in 2024, with contract chipmaker Taiwan Semiconductor Manufacturing Co. (TSMC) ranking third, according to TWSE data. The data released Friday showed that CTBC Financial paid an average of NT$95.73 million in board member compensation in 2024, ahead of multi-layer ceramic capacitor (MLCC) maker Yageo Corp., which paid NT$78.25 million, and TSMC, which paid NT$50.72 million. Despite paying the highest board compensation, CTBC Financial posted earnings per share of NT$3.64 in 2024, far below Yageo’s NT$38.13 and TSMC’s NT$45.25, the data showed. CNA file photo KGI Financial Holding Co. ranked fourth, paying its board members an average of NT$50.23 million in 2024, followed by Yuanta Financial Holding Co. at NT$44.33 million, the TWSE said. Rounding out the top 10 were smartphone camera lens supplier Largan Precision Co., Fubon Financial Holding Co., Hotai Motor Co., TS Financial Holding Co. and Taichung Bank, with average board member compensation ranging between NT$30 million and NT$40 million. On the over-the-counter market, engineering system integration services provider Acter Co. paid the highest average board compensation at NT$15.59 million in 2024, followed by gaming software developer International Games System Co. at NT$15.42 million and Yuanta Futures Co. at NT$4.91 million.
An insider at a top homebuilding company recently sold over 70,000 shares, as the builder looks to recover from a rough 2025. On Jan. 21 and Jan. 22, 2026, 10% Owner William Radford Lovett II reported the indirect sale of 71,742 shares of Dream Finders Homes (DFH 1.18%), representing ~$1.4 million in open-market transactions, according to a SEC Form 4 filing. Transaction summary Metric Value Share...
An insider at a top homebuilding company recently sold over 70,000 shares, as the builder looks to recover from a rough 2025. On Jan. 21 and Jan. 22, 2026, 10% Owner William Radford Lovett II reported the indirect sale of 71,742 shares of Dream Finders Homes (DFH 1.18%), representing ~$1.4 million in open-market transactions, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (indirect) 71,742 Transaction value $1.4 million Post-transaction shares (direct) 22,349 Post-transaction value (direct) $432,453 Transaction value based on SEC Form 4 weighted average purchase price ($19.51); post-transaction value based on Jan. 22, 2026 market close ($19.35). Key questions How significant was this sale relative to Lovett’s historical trading activity? The 71,742 shares sold exceed Lovett’s historical median sell transaction of 50,076 shares since December 2024. The 71,742 shares sold exceed Lovett’s historical median sell transaction of 50,076 shares since December 2024. How were the shares sold? All shares sold were held indirectly through the W. Radford Lovett II GST Exempt Trust, with Lovett serving as sole trustee. Company overview Metric Value Revenue (TTM) $4.67 billion Net income (TTM) $274.23 million *1-year price change -21.17% * 1-year price change calculated using Jan. 31, 2026 as the reference date. Company snapshot Dream Finders Homes is a large-scale homebuilder that also offers insurance agency services and mortgage banking solutions across the U.S. It focuses on single-family homes and caters to first- and second-time home buyers. The company sells homes through its various brands, including DF Luxury, Craft Homes, and Coventry Homes. What this transaction means for investors Dream Finders Home is on pace to have one of its worst years, profitability-wise, in fiscal year 2025. For three straight quarters, the company’s earnings per share (EPS) have declined year over year, the first time since the last three quarters of FY 2021. Its...
XRP was one of the most intriguing cryptocurrencies from 2025. After its strongest rally in seven years, XRP (XRP 2.36%) has entered 2026 with an uncertain future. What once looked like the next breakout digital token is at risk of significant downward pressure in the months ahead. Let's reassess XRP's performance from last year and explore why further volatility could be on the horizon. Is XRP ab...
XRP was one of the most intriguing cryptocurrencies from 2025. After its strongest rally in seven years, XRP (XRP 2.36%) has entered 2026 with an uncertain future. What once looked like the next breakout digital token is at risk of significant downward pressure in the months ahead. Let's reassess XRP's performance from last year and explore why further volatility could be on the horizon. Is XRP about to turn into a falling knife? Read on to find out. Why did XRP soar in early 2025? During the first half of 2025, XRP surged by about 70%, reaching a price of $3 for the first time since 2018. However, the token plummeted during the second half of the year, ultimately ending 2025 down 10%. In reality, XRP's rally had nothing to do with the underlying fundamentals of the token. Rather, its run-up was entirely driven by a speculative narrative. XRP is a cryptocurrency that is issued by the payments company Ripple. For years, Ripple and the Securities and Exchange Commission (SEC) had been in a legal tiff around whether XRP should be considered a security -- similar to a stock or bond -- when it's sold. Last year, the SEC dropped its lawsuit against Ripple, giving the company -- and the crypto landscape more broadly -- a major victory over a tough regulatory environment. It didn't take long for retail investors to create a narrative that XRP had become legitimized and could soon become the next cornerstone of institutional crypto portfolios. XRP has a structural issue, and investors are finally realizing it I see two primary headwinds that influenced XRP's reversal last year. First, the broader cryptocurrency market witnessed heavy selling pressure as capital began rotating into safe havens like gold and silver, as well as more-durable secular themes such as artificial intelligence stocks. The token's value proposition could actually be working against it. The crypto landscape is riddled with loads of altcoins that have little or no utility. XRP actually does serve a purpo...
A landslide earlier this week collapsed several mines at a major coltan mining site in the eastern Democratic Republic of Congo (DRC), leaving at least 200 people dead, rebel authorities said on Saturday. The collapse took place on Wednesday at the Rubaya mines, which are controlled by the M23 rebels, said Lumumba Kambere Muyisa, spokesman for the rebel-appointed governor of North Kivu province. H...
A landslide earlier this week collapsed several mines at a major coltan mining site in the eastern Democratic Republic of Congo (DRC), leaving at least 200 people dead, rebel authorities said on Saturday. The collapse took place on Wednesday at the Rubaya mines, which are controlled by the M23 rebels, said Lumumba Kambere Muyisa, spokesman for the rebel-appointed governor of North Kivu province. He said the landslide was caused by heavy rains. Advertisement “For now, there are more than 200 dead, some of whom are still in the mud and have not yet been recovered.” Muyisa added that several people were injured and taken to three health facilities in the town of Rubaya, while ambulances were expected to transfer the wounded on Saturday to Goma, the nearest city, around 50km (30 miles) away. A labourer carries a sack of ore at a coltan mine in the town of Rubaya - controlled by M23 rebels - in the DRC in March 2025. Photo: Reuters The rebel-appointed governor of North Kivu has temporarily halted artisanal mining on the site and ordered the relocation of residents who had built shelters near the mine, Muyisa said.
There's no need to hurry in buying this biotech stock. BioMarin Pharmaceutical's (BMRN 0.84%) website doesn't show any scheduled events on its calendar over the next month. However, that means nothing. The drugmaker will almost certainly report its 2025 full-year and fourth-quarter results in the coming weeks. Last year, BioMarin provided its Q4 update on the third Wednesday in February. The compa...
There's no need to hurry in buying this biotech stock. BioMarin Pharmaceutical's (BMRN 0.84%) website doesn't show any scheduled events on its calendar over the next month. However, that means nothing. The drugmaker will almost certainly report its 2025 full-year and fourth-quarter results in the coming weeks. Last year, BioMarin provided its Q4 update on the third Wednesday in February. The company could choose the same day this year. If it does, investors may want to circle Feb. 18, 2026, on their calendars. But should you buy the biotech stock before then? Buy, buy, buy? One reason to consider buying BioMarin before its Q4 results are announced is that rare-disease drug Voxzogo is expected to have a strong quarter. CFO Brian Mueller said in the company's Q3 earnings call that Voxzogo revenue should "reach its highest level of the year" in Q4. The primary concern for most investors when buying a stock before a quarterly earnings announcement is the possibility that the company will fall short of Wall Street's estimates. But BioMarin arguably lowered the chances of a negative surprise by raising the lower end of its 2025 revenue guidance to $3.15 billion, based in part on "expectations for the fourth quarter." The midpoint of the drugmaker's guidance range reflects double-digit year-over-year revenue growth. Another reason to invest in BioMarin sooner rather than later isn't related to the Q4 update. The company has several potential catalysts on the way. For example, the U.S. Food and Drug Administration (FDA) set a PDUFA date of Feb. 28, 2026, for an approval decision on Palynziq in the treatment of adolescents ages 12 through 17 with phenylketonuria. European Union approval for this indication could also come in the first half of the year. Additionally, BioMarin expects to announce results from two Phase 3 clinical studies in the first half of 2026. It also plans to file for full FDA approval of Voxzogo for the treatment of achondroplasia. Expand NASDAQ : BMRN B...
Here's a sneak peek into the future. Millions of Americans collect monthly retirement benefits from Social Security. And for many recipients, those benefits constitute the bulk of their retirement income. Some retirees, in fact, have only Social Security to cover their bills. For this reason, Social Security's annual cost-of-living adjustments, or COLAs, are extremely important. Social Security be...
Here's a sneak peek into the future. Millions of Americans collect monthly retirement benefits from Social Security. And for many recipients, those benefits constitute the bulk of their retirement income. Some retirees, in fact, have only Social Security to cover their bills. For this reason, Social Security's annual cost-of-living adjustments, or COLAs, are extremely important. Social Security benefits are eligible for COLAs every year; these are calculated and applied automatically based on inflation. This is very different from the way things worked decades ago, when lawmakers actually had to vote on whether to boost Social Security benefits. For retirees who rely heavily on Social Security, annual COLAs are extremely important. And if you're on Social Security, you may be wondering what your 2027 COLA will look like -- even though 2026 has only just gotten started. There are some initial estimates of 2027's Social Security COLA. But you may not like what you hear. What the experts say so far In 2026, Social Security benefits got a 2.8% COLA. Based on recent inflation readings, the Senior Citizen League, an advocacy group, projects that Social Security benefits will get a 2.5% COLA in 2027. Obviously, a smaller COLA in the new year would be a big disappointment. But it's way too soon to panic over a stingy COLA in 2027. Social Security COLAs are based on inflation readings from the months of July, August, and September. Inflation readings leading up to those months can give some clues as to what to expect from the upcoming COLA. But ultimately, it's too early in the year to land on a 2027 COLA with any degree of certainty. Don't expect great things Even if next year's Social Security COLA comes in higher than the current 2.5% projection, it's important to have realistic expectations. You may want to assume that the adjustment won't do much, or anything, to improve your finances. First, Social Security COLAs aren't actually designed to help seniors get ahead finan...
warat42/iStock via Getty Images ProKidney Corp. ( PROK ) is technically a kidney disease cell-therapy company. They develop their leading drug candidate called Rilparencel. This asset is an autologous kidney cell therapy for chronic kidney disease (CKD) related to type 2 diabetes (T2D). The drug is in pivotal Phase 3 trials under PROACT 1, which is intended to support a potential accelerated appro...
warat42/iStock via Getty Images ProKidney Corp. ( PROK ) is technically a kidney disease cell-therapy company. They develop their leading drug candidate called Rilparencel. This asset is an autologous kidney cell therapy for chronic kidney disease (CKD) related to type 2 diabetes (T2D). The drug is in pivotal Phase 3 trials under PROACT 1, which is intended to support a potential accelerated approval submission. After that, PROK promptly plans to do a longer follow-up study and seek full FDA approval. The FDA has confirmed that the estimated glomerular filtration rate (eGFR) slope can serve as a surrogate endpoint to support a Biologics License Application (BLA) under an accelerated approval pathway. So, on balance, I feel it’s still fair to remain bullish on the stock as long as you have a favorable long-term view on Rilparencel. Promising Accelerated Approval Odds ProKidney Corp. is a clinical-stage biotech working on an autologous cell therapy to preserve kidney function. This can be life-changing for patients who present advanced chronic kidney disease (CKD), particularly associated with type 2 diabetes (T2D). The company was founded back in 2015 and is currently headquartered in Winston-Salem, North Carolina. I also previously covered PROK in January last year with a “Buy” rating, and since then, the stock has appreciated by roughly 17.9%. So, I thought it was worthwhile updating my analysis on this name. Source: Corporate Presentation. January 2026. As a quick recap, PROK’s core candidate is Rilparencel (REACT), which is a patient-derived cell therapy. They essentially take a percutaneous kidney cortex biopsy, then grow and enrich the selected viable renal cells ex vivo. After that, PROK’s approach formulates these cells in a gelatin-based hydrogel and finally injects the cells back into the kidney cortex. This is done during an outpatient procedure guided by a computed tomography scan (CT). This way, PROK’s therapy aims to slow the decline of kidney function ...
Josh Kelly has always presented as confident but looks can be deceiving. In 2021, Kelly appeared to have the world at his feet as he prepared to face David Avanesyan for the European welterweight title. Kelly was undefeated in 10 fights as a professional and had his sights set on the top tier of the division. During that run, which included six stoppage wins, Kelly - nicknamed 'Pretty Boy' - caugh...
Josh Kelly has always presented as confident but looks can be deceiving. In 2021, Kelly appeared to have the world at his feet as he prepared to face David Avanesyan for the European welterweight title. Kelly was undefeated in 10 fights as a professional and had his sights set on the top tier of the division. During that run, which included six stoppage wins, Kelly - nicknamed 'Pretty Boy' - caught the eye by dancing around the ring and taunting opponents. But behind the scenes all was not well. He was battling with chronic hypochondria - known formally as illness anxiety disorder - a condition that is characterised by an excessive, disabling fear of having a serious undiagnosed medical illness. "I should have seen it coming even before that fight [against Avaneysan]" Kelly told BBC Sport. "I used to go into fight week and have Lemsips stacked up - I'd have three or four a day and it was for no reason apart from thinking what if I get sick? "That was just because I was putting pressure on myself to perform the best. I was thinking that everything had to be perfect for me to perform my best."
Jose Luis Pelaez Inc/DigitalVision via Getty Images Benitec Biopharma Inc. ( BNTC ) is a clinical-stage genetic medicine company that develops one lead asset: BB-301. This candidate is intended for treating OPMD-related dysphagia, which is a progressive condition that can potentially lead to death. This therapy aims to be a single dose to silence the mutant gene that produces the disease while sup...
Jose Luis Pelaez Inc/DigitalVision via Getty Images Benitec Biopharma Inc. ( BNTC ) is a clinical-stage genetic medicine company that develops one lead asset: BB-301. This candidate is intended for treating OPMD-related dysphagia, which is a progressive condition that can potentially lead to death. This therapy aims to be a single dose to silence the mutant gene that produces the disease while supplying a functional copy. That’s why BNTC calls this approach a “silence and replace” mechanism of action. BB-301’s cohort 1 from its Phase 1b/2a trial is composed of 6 patients, and it has presented positive efficacy and safety results. BNTC anticipates a meeting with the FDA in mid-2026 to confirm the design of a pivotal study. So, for the most part, I believe BNTC now offers a much more compelling bet at these levels for new investors, which is why I lean bullish at this point. Treatment By Silencing And Replacement Benitec Biopharma Inc. is a clinical-stage biotech working on a genetic treatment for oculopharyngeal muscular dystrophy [OPMD] that causes dysphagia (swallowing impairment). BNTC was incorporated back in 2019 and is currently headquartered in Hayward, California. I previously covered BNTC in October 2024, and since then, the stock has appreciated by approximately 32.7%, so I thought it was worthwhile revisiting this name. Source: Corporate Presentation. January 2026. As a quick recap, OPMD is a rare degenerative muscle disorder, where one mutated copy of a gene can cause the disease. The target gene is the poly(a)-binding protein nuclear 1 (PABPN1), which is involved in messenger RNA (mRNA) processing. Its mutation disrupts this fundamental RNA-processing function and contributes to muscle pathology. The onset of OPMD is in the 40s and 50s, with symptoms such as eyelid drooping, weakness in the hips and shoulders, and dysphagia, causing difficulty swallowing, often with choking during meals. Unfortunately, progressive dysphagia impacts 97% of OPMD patients a...